KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Goodwill & Intangibles: 2010-2025

Historic Goodwill & Intangibles for TherapeuticsMD (TXMD) over the last 10 years, with Sep 2025 value amounting to $6.3 million.

  • TherapeuticsMD's Goodwill & Intangibles fell 1.97% to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year decrease of 1.97%. This contributed to the annual value of $6.4 million for FY2024, which is 19.95% down from last year.
  • Per TherapeuticsMD's latest filing, its Goodwill & Intangibles stood at $6.3 million for Q3 2025, which was down 0.51% from $6.3 million recorded in Q2 2025.
  • Over the past 5 years, TherapeuticsMD's Goodwill & Intangibles peaked at $48.4 million during Q3 2022, and registered a low of $6.3 million during Q3 2025.
  • In the last 3 years, TherapeuticsMD's Goodwill & Intangibles had a median value of $6.4 million in 2024 and averaged $6.7 million.
  • Per our database at Business Quant, TherapeuticsMD's Goodwill & Intangibles surged by 650.61% in 2021 and then slumped by 86.26% in 2023.
  • TherapeuticsMD's Goodwill & Intangibles (Quarterly) stood at $8.2 million in 2021, then increased by 4.34% to $8.5 million in 2022, then declined by 6.70% to $8.0 million in 2023, then dropped by 19.95% to $6.4 million in 2024, then decreased by 1.97% to $6.3 million in 2025.
  • Its last three reported values are $6.3 million in Q3 2025, $6.3 million for Q2 2025, and $6.3 million during Q1 2025.